Early effectiveness of heptavalent conjugate pneumococcal vaccination on invasive pneumococcal disease after the introduction in the Danish Childhood Immunization Programme

Vaccine

Volumn 28, Issue 14, 2010, Pages 2642-2647

  Harboe, Zitta B ^a   Valentiner Branth, Palle ^a   Benfield, Thomas L ^b,c   Christensen, Jens Jørgen ^a   Andersen, Peter H ^a   Howitz, Michael ^a   Krogfelt, Karen A ^a   Lambertsen, Lotte ^a   Konradsen, Helle B ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Invasive pneumococcal disease; Mortality; PCV7 effectiveness

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; PNEUMOCOCCUS VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EFFICACY; HEALTH SURVEY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MORTALITY; PNEUMOCOCCAL INFECTION; PNEUMOCOCCAL MENINGITIS; PRESCHOOL CHILD; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; SCHOOL CHILD; SEROTYPE; VACCINATION;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DENMARK; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; YOUNG ADULT;

EID: 77649185872     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.01.017     Document Type: Article

References (44)

1. Pneumococcal conjugate vaccine for childhood immunization-WHO position paper. 2007;82:p. 93.
2. Koedel U., Scheld W.M., and Pfister H.W. Pathogenesis and pathophysiology of pneumococcal meningitis. Lancet Infect Dis 2 12 (2002) 721-736
3. Purulent Meningitis 2007 [Bacterial Meningitis 2007]. EPI-NEWS nr 45, 2008. Availabe online at http://ssi.dk/sw60065.asp.
4. File J. Community-acquired pneumonia. The Lancet 362 9400 (2003) 1991-2001
5. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease-United States, 1998-2003. MMWR 2005; 54:893-916.
6. Hsu H.E., Shutt K.A., Moore M.R., Beall B.W., Bennett N.M., Craig A.S., et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med 360 3 (2009) 244-256
7. Lexau C.A., Lynfield R., Danila R., Pilishvili T., Facklam R., Farley M.M., et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 294 16 (2005) 2043-2051
8. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., and Lynfield R. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 348 18 (2003) 1737-1746
9. Grijalva C.G., Nuorti J.P., Arbogast P.G., Martin S.W., Edwards K.M., and Griffin M.R. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. The Lancet 369 9568 (2007) 1179-1186
10. Eskola J., Kilpi T., Palmu A., Jokinen J., Haapakoski J., Herva E., et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 344 6 (2001) 403-409
11. Dagan R., and Klugman K.P. Impact of conjugate pneumococcal vaccines on antibiotic resistance. Lancet Infect Dis 8 12 (2008) 785-795
12. Guevara M., Barricarte A., Perez B., Arriazu M., Garcia C.M., and Castilla J. Heptavalent-pneumococcal conjugate vaccine (Prevenar). Differences in effectiveness between populations. An Sist Sanit Navar 31 2 (2008) 171-192
13. Ardanuy C., Tubau F., Pallares R., Calatayud L., Dominguez M.A., Rolo D., et al. Epidemiology of invasive pneumococcal disease among adult patients in barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction, 1997-2007. Clin Infect Dis 48 1 (2009) 57-64
14. Singleton R.J., Hennessy T.W., Bulkow L.R., Hammitt L.L., Zulz T., Hurlburt D.A., et al. Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 297 16 (2007) 1784-1792
15. Hendrickson D.J., Blumberg D.A., Joad J.P., Jhawar S., and McDonald R.J. Five-fold increase in pediatric parapneumonic empyema since introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J 27 11 (2008) 1030-1032
16. Jacobs M.R., Good C.E., Bajaksouzian S., and Windau A.R. Emergence of Streptococcus pneumoniae serotypes 19A, 6C, and 22F and serogroup 15 in Cleveland, Ohio, in relation to introduction of the protein-conjugated pneumococcal vaccine. Clin Infect Dis 47 11 (2008) 1388-1395
17. Hicks L.A., Harrison L.H., Flannery B., Hadler J.L., Schaffner W., Craig A.S., et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 196 9 (2007) 1346-1354
18. Moore M.R., Gertz Jr. R.E., Woodbury R.L., Barkocy-Gallagher G.A., Schaffner W., Lexau C., et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis 197 7 (2008) 1016-1027
19. Muñoz Almagro C., Jordan I., Gene A., Latorre C., Garcia-Garcia J., and Pallares R. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis 46 2 (2008) 174-182
20. Albrich W.C., Baughman W., Schmotzer B., and Farley M.M. Changing characteristics of invasive pneumococcal disease in Metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine. Clin Infect Dis 44 12 (2007) 1569-1576
21. Alanee S.R., McGee L., Jackson D., Chiou C.C., Feldman C., Morris A.J., et al. Association of serotypes of Streptococcus pneumoniae with disease severity and outcome in adults: an international study. Clin Infect Dis 45 1 (2007) 46-51
22. Harboe Z.B., Thomsen R.W., Riis A., Valentiner-Branth P., Christensen J.J., Lambertsen L., et al. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med 6 5 (2009) e1000081
23. Rückinger S., von K.R., Siedler A., and van der L.M. Association of serotype of Streptococcus pneumoniae with risk of severe and fatal outcome. Pediatr Infect Dis J 28 2 (2009) 118-122
24. Worldwide progress in introducing pneumococcal conjugate vaccine, 2000-2008. Weekly Epidemiological Record, Vol. 83(43), p. 388-392, 5p.
25. Pneumokokvaccine i det Danske Børnevaccinationsprgram [Pneumococcal vaccine in the Danish childhood vaccination programme] EPI-NEWS No. 38, 2008. Availabe at: http://www.ssi.dk/sw58939.asp.
26. Høgh B., Konradsen H.B., Kristensen K., Hansen K.G., Kofoed P.E., Nielsen V.R., et al. Pneumococcal vaccination of high-risk children [Pneumokokvaccination af risikobørn]. Ugeskr Læger 165 42 (2003) 4032
27. Bingen E., Levy C., Varon E., De la Rocque F., Boucherat M., d'Athis P., et al. Pneumococcal meningitis in the era of pneumococcal conjugate vaccine implementation. Eur J Clin Microbiol Infect Dis 27 3 (2008) 191-199
28. Casado-Flores J., Rodrigo C., Aristegui J., Martinon J.M., Fenoll A., and Mendez C. Decline in pneumococcal meningitis in Spain after introduction of the heptavalent pneumococcal conjugate vaccine. Pediatr Infect Dis J 27 11 (2008) 1020-1022
29. Levy C., Varon E., Bingen E., Picard C., De la Rocque F., Aujard Y., et al. Pneumococcal meningitis in children in France: 832 cases from 2001 to 2007. Arch Pediatr 15 Suppl. 3 (2008) S111-S118
30. Tsai C.J., Griffin M.R., Nuorti J.P., and Grijalva C.G. Changing epidemiology of pneumococcal meningitis after the introduction of pneumococcal conjugate vaccine in the United States. Clin Infect Dis 46 11 (2008) 1664-1672
31. Vestrheim D.F., Lovoll O., Aaberge I.S., Caugant D.A., Hoiby E.A., Bakke H., et al. Effectiveness of a 2 + 1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine 26 26 (2008) 3277-3281
32. Lepoutre A., Varon E., Georges S., Gutmann L., and Levy-Bruhl D. Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001-2006. Euro Surveill 13 35 (2008)
33. Pedersen C.B., Gotzsche H., Moller J.O., and Mortensen P.B. The Danish Civil Registration System. A cohort of eight million persons. Dan Med Bull 53 4 (2006) 441-449
34. Pebody R.G., Hellenbrand W., D'Ancona F., and Ruutu P. Pneumococcal disease surveillance in Europe. Euro Surveill 11 9 (2006) 171-178
35. Harboe Z.B., Valentiner-Branth P., Benfield T.L., Christensen J.J., Hjuler T., Kaltoft M., et al. Estimated effect of pneumococcal conjugate vaccination on invasive pneumococcal disease and associated mortality. Denmark 2000-2005. Vaccine 26 29-30 (2008) 3765-3771
36. Henrichsen J. Six newly recognized types of Streptococcus pneumoniae. J Clin Microbiol 33 10 (1995) 2759-2762
37. Sorensen U.B. Typing of pneumococci by using 12 pooled antisera. J Clin Microbiol 31 8 (1993) 2097-2100
38. DiTeKiPol/Hib-vaccination, tilslutning ultimo 2007 [DTap/IPV/HIB vaccination coverage by end 2007] EPI-NEWS No. 37, 2008. Availabe at: http://www.ssi.dk/sw58794.asp.
39. De Carvalho G.H., Muscat M., Monnet D.L., Giesecke J., and Lopalco P.L. Use of seven-valent pneumococcal conjugate vaccine (PCV7) in Europe, 2001-2007. Euro Surveill 14 12 (2009)
40. Kaltoft M.S., Zeuthen N., and Konradsen H.B. Epidemiology of invasive pneumococcal infections in children aged 0-6 years in Denmark: a 19-year nationwide surveillance study. Acta Paediatr Suppl 89 435 (2000) 3-10
41. Rückinger S., van der Linden M., Reinert R.R., von Kries R., Burckhardt F., Siedler A., et al. Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany. Vaccine 27 31 (2009) 4136-4141
42. DANMAP 2008. Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, foods and humans in Denmark. ISSN 1600-2032. Available at www.danmap.org.
43. Feikin D.R., and Klugman K.P. Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. Clin Infect Dis 35 5 (2002) 547-555
44. Hausdorff W.P., Feikin D.R., and Klugman K.P. Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis 5 2 (2005) 83-93